(Q57579457)

English

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

scientific article published on 28 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Michelino De Laurentiis

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Joseph Gligorov

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Gunter von Minckwitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Eduard Vrdoljak

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Norbert Marschner

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Christoph Zielinski

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristian Villanueva

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gilles Romieu

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

István Lang

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Corinne Veyret

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sabine de Ducla

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ulrich Freudensprung

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Stefanie Srock

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

28 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1269-1278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF inhibition: insights from preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer: The nuances of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70439-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579457&oldid=1970342815"